An experimental vaccine for kidney cancer is off to a promising start. In data from a Phase I trial released this week, the ...

As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...

A complainant shared four third-party posts on X (formerly Twitter) and two online articles with the PMCPA to make the case ...

The Agreement provides participating countries with the opportunity to diversify their mRNA COVID-19 vaccine supply and gain access to pre-filled syringe vaccine formats ...

Moderna stock has been under pressure amid ... company's continued dependence on its COVID-19 shot, commercialized as Spikevax. Although the company has made progress in reducing costs and ...

Moderna fell to a new 52-week low after some disappointing news. The short explanation is that demand for Moderna's COVID-19 vaccine has plunged since the end of the pandemic. Moderna still has ...

The firm noted Moderna's reduced 2024 sales forecast of $3.0–$3.1 billion, down from $3.0–$3.5 billion, driven by declines in Spikevax (COVID vaccine) sales and minimal contributions from mRESVIA (RSV ...

Moderna is down 80% from its 52-week high as ... like potential approval of a next-gen COVID vaccine and a possible label expansion for the RSV vaccine due in 2025. An opportunity for an early ...

The firm noted Moderna's reduced 2024 sales forecast of $3.0–$3.1 billion, down from $3.0–$3.5 billion, driven by declines in Spikevax (COVID vaccine) sales and minimal contributions from ...

Moderna's COVID-19 vaccine, Spikevax, drove £1.47 billion ($1.8 billion) in sales during Q3 2024 due to robust demand in the US. Revenues from its latest respiratory syncytial virus vaccine ...

Moreover, while Moderna is working on strategic priorities such as driving the use of Spikevax and mResvia, seeking 10 product approvals over the next three years, and improving cost efficiencies ...

This includes more than $3.0 billion in Spikevax® sales ... to continue on the open label extension study. The Company began generating registrational trial data in 2024. Methylmalonic acidemia (MMA) ...